Dutch Medical Pioneer Secures €20.5 Million to Transform Kidney Dialysis Treatment
Eindhoven, Thursday 27 August 2026
Eindhoven-based Xeltis has raised €20.5 million, including support from Invest-NL, to advance a pioneering implant that stimulates patients’ bodies to naturally regenerate their own blood vessels.
A Regenerative Leap in Cardiovascular Care
The Eindhoven-based medical technology company Xeltis is pioneering a paradigm shift in vascular medicine by developing implants that stimulate the human body to naturally regenerate its own blood vessels [1]. For patients undergoing kidney dialysis, who frequently suffer from complications related to traditional vascular access methods, this technology could prove transformative [1]. By utilizing the body’s natural healing processes, the restorative cardiovascular implant, known as aXess™, aims to significantly reduce the risk of infections and lower the frequency of invasive follow-up procedures compared to existing clinical options [1].
Securing Capital for the Growth Phase
To transition this innovative technology from clinical development to commercial application, Xeltis has successfully raised €20.5 million in its latest funding round [1]. Dutch impact investor Invest-NL has committed a €5 million follow-on investment to this round, representing 24.39% of the total capital raised [1]. Invest-NL has been a key backer of Xeltis since 2023, reflecting a long-term commitment to high-tech medical innovations within the Netherlands [1]. The funding round was led by new investor Horizon 3 Healthcare, alongside participation from the European Innovation Council, VI Partners, EQT Life Sciences, DaVita, and other existing shareholders [1].
Scaling Operations and Expanding Global Reach
With the commercial introduction of aXess™ in Europe, Xeltis is entering a critical growth phase [1]. The newly secured capital will be used to accelerate the market availability of the treatment across European countries, scale up manufacturing capabilities, and complete ongoing clinical trials in the United States [1]. Beyond dialysis access, Xeltis is actively leveraging its proprietary regenerative platform to develop alternative cardiovascular applications [1]. This long-term financial support is designed to improve patient outcomes while simultaneously reducing healthcare costs associated with chronic disease management and subsequent medical interventions [1].